thiotepa has been researched along with Glioblastoma in 8 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between April 1986 and March 1989, ten patients under 21 years of age with histologically confirmed malignant astrocytoma, received marrow-ablative chemotherapy with either thiotepa and Etoposide (five patients) or thiotepa, Etoposide and BCNU (five patients), followed by bone marrow 'rescue'." | 5.06 | High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. ( August, C; Bayever, E; Finlay, JL; Freid, A; Kamani, N; Kramer, E; Packer, R; Rorke, L; Sutton, L; Zimmerman, R, 1990) |
| " We report our experience with a 19-year-old girl with glioblastoma multiforme (GBM) of the deep temporal region recurring 6 months after completing an intensive treatment that included preradiation chemotherapy (chemotherapy as a preradiation "sandwich" phase) with a myeloablative course of thiotepa, tumor bed radiotherapy and postradiation maintenance chemotherapy." | 3.73 | A case of relapsing glioblastoma multiforme responding to vinorelbine. ( Biassoni, V; Casanova, M; Gandola, L; Massimino, M; Spreafico, F, 2006) |
| "Nineteen patients with primary malignant gliomas were treated with thioTEPA." | 3.66 | Phase II evaluation of thioTEPA for treatment of central nervous system tumors. ( Edwards, MS; Levin, VA; Pischer, TL; Seager, ML; Wilson, CB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| MAHALEY, MS | 1 |
| ODOM, GL | 1 |
| WOODHALL, B | 1 |
| Biassoni, V | 1 |
| Casanova, M | 1 |
| Spreafico, F | 1 |
| Gandola, L | 1 |
| Massimino, M | 1 |
| Grovas, AC | 1 |
| Boyett, JM | 1 |
| Lindsley, K | 1 |
| Rosenblum, M | 1 |
| Yates, AJ | 1 |
| Finlay, JL | 2 |
| Edwards, MS | 1 |
| Levin, VA | 1 |
| Seager, ML | 1 |
| Pischer, TL | 1 |
| Wilson, CB | 2 |
| August, C | 1 |
| Packer, R | 1 |
| Zimmerman, R | 1 |
| Sutton, L | 1 |
| Freid, A | 1 |
| Rorke, L | 1 |
| Bayever, E | 1 |
| Kamani, N | 1 |
| Kramer, E | 1 |
| Mark, JB | 1 |
| Flanigan, S | 1 |
| Sato, O | 1 |
| Hoshino, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thiotepa and Glioblastoma
| Article | Year |
|---|---|
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil | 1999 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
6 other studies available for thiotepa and Glioblastoma
| Article | Year |
|---|---|
HISTOLOGICAL CHANGES AFTER REGIONAL CHEMOTHERAPY. BRAIN AND FACE TUMORS.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regio | 1963 |
A case of relapsing glioblastoma multiforme responding to vinorelbine.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combin | 2006 |
Phase II evaluation of thioTEPA for treatment of central nervous system tumors.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Drug Evaluation; Glioblastoma; Glioma; Humans; Midd | 1979 |
Chemotherapy of malignant brain tumors.
Topics: Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Regional Perfusion; Chlorambucil; Glioblast | 1966 |
[Chemotherapy of malignant brain tumors by intermittent and continuous intra-arterial infusion of antitumor agents--clinical study].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Arteries; Brain Edema; Brain Neoplasms; C | 1966 |
Current trends in the chemotherapy of brain tumors with special reference to glioblastomas.
Topics: Alkaloids; Antibiotics, Antineoplastic; Antineoplastic Agents; Azaguanine; Blood Vessel Prosthesis; | 1969 |